The term “eukaryote” is derived from the Greek name of the nucleus (eu) and refers to single-celled as well as multicellular organisms with complex cells with a nucleus and other advanced organelles. The nuclei of these cells contain the genetic material organized into chromosomes. Animals, plants, fungi, and algae, for instance, are all eukaryotes. The cells of eukaryotes contain cell organelles such as Golgi apparatus, mitochondria, lysosomes, and ribosomes, and – among plants and algae – chloroplast.
Obtain the Forward Looking Perspective of Eukaryotic Expression Systems Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2923
A eukaryotic expression system is one of the basic components of a protein expression system. A protein expression system is a crucial part of proteomics, which is useful in the research and expression of genetically engineered recombinant proteins in various cells. These proteins are synthesized depending upon the functional need of a cell, and regulated in the body/cell.
The DNA stores the basic designs for proteins, which are decoded by transcriptional processes to produce mRNA, and the mRNA codes a message that helps in the synthesis of a protein. Apart from eukaryotic expression systems, another expression system that is a basic component of the protein expression system is the prokaryotic expression system. Out of the two expression systems, prokaryotic expression systems hold a larger share in terms of revenue. However, according to the report, the eukaryotic expression systems market is anticipated to witness the highest CAGR in the period from 2014 to 2020.
The market for eukaryotic expression systems is driven by the extensive use of these systems in the manufacturing of recombinant proteins for research and therapeutics, as well as for drugs development. The market for eukaryotic expression systems is expected to grow rapidly for the rest of the forecast period, owing to the rising incidence of complex diseases such as cancer and cardiovascular diseases. Since therapeutics can be developed for these complex diseases using eukaryotic expression systems, the market for eukaryotic expression systems is expected to expand at a steady rate in the coming years. Additionally, the increasing research and development for developing more advanced eukaryotic expression systems opens up new opportunities for the market.
According to the report, drivers for the eukaryotic expression systems market include the high demand from the pharmaceutical industry and the development of the fields of biologics and proteomics.
Key players profiled in the report are: Promega Corporation, Agilent Technologies, Inc., New England BioLabs, Inc., Merck Millipore, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., QIAGEN, Sigma-Aldrich Corporation, Jena Bioscience GmbH, Life Technologies Corporation, and Takara Bio, Inc.